Ensign Peak Advisors Inc Raises Stock Position in Altimmune, Inc. (NASDAQ:ALT)

Ensign Peak Advisors Inc boosted its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 39.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 454,981 shares of the company's stock after buying an additional 128,204 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.64% of Altimmune worth $3,280,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new position in Altimmune in the fourth quarter valued at $45,000. Virtus ETF Advisers LLC purchased a new stake in shares of Altimmune in the 4th quarter valued at about $60,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Altimmune in the 4th quarter valued at about $72,000. 180 Wealth Advisors LLC purchased a new stake in Altimmune in the fourth quarter valued at approximately $78,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Altimmune in the fourth quarter valued at approximately $81,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Price Performance

Shares of NASDAQ:ALT traded down $0.00 during trading on Tuesday, reaching $5.50. The company had a trading volume of 382,941 shares, compared to its average volume of 2,813,645. Altimmune, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $11.16. The stock's fifty day moving average price is $5.11 and its 200 day moving average price is $6.55. The firm has a market capitalization of $445.85 million, a price-to-earnings ratio of -3.53 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the firm posted ($0.34) EPS. On average, equities analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Insider Activity

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at approximately $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALT. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. William Blair reissued a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of "Buy" and a consensus price target of $20.20.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.